Oral Oncology, Journal Year: 2021, Volume and Issue: 121, P. 105332 - 105332
Published: June 14, 2021
Language: Английский
Clinical Cancer Research, Journal Year: 2021, Volume and Issue: 28(2), P. 350 - 359
Published: Oct. 26, 2021
Abstract Purpose: In locally advanced p16+ oropharyngeal squamous cell carcinoma (OPSCC), (i) to investigate kinetics of human papillomavirus (HPV) circulating tumor DNA (ctDNA) and association with progression after chemoradiation, (ii) compare the predictive value ctDNA imaging biomarkers MRI FDG-PET. Experimental Design: Serial blood samples were collected from patients AJCC8 stage III OPSCC (n = 34) enrolled on a randomized trial: pretreatment; during chemoradiation at weeks 2, 4, 7; posttreatment. All also had dynamic-contrast-enhanced diffusion-weighted MRI, as well FDG-PET scans pre-chemoradiation week 2 chemoradiation. values analyzed for prediction freedom (FFP), correlations aggressive subvolumes low volume (TVLBV) apparent diffusion coefficient (TVLADC), metabolic (MTV) using Cox proportional hazards model Spearman rank correlation. Results: Low pretreatment an early increase in compared baseline significantly associated superior FFP (P < 0.02 P 0.05, respectively). At 4 or 7, neither counts nor clearance 0.8). Pretreatment correlated nodal TVLBV, TVLADC, MTV 0.03), while these metrics primary tumor. Multivariate analysis showed that performed comparably predict FFP. Conclusions: Early definitive may therapy response OPSCC.
Language: Английский
Citations
78
Cancer, Journal Year: 2023, Volume and Issue: 129(18), P. 2817 - 2827
Published: May 10, 2023
Development of evidence-based post-treatment surveillance guidelines in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) is limited by comprehensive documentation patterns recurrence metastatic spread.A retrospective analysis patients diagnosed with R/M HNSCC at a National Cancer Institute-designated cancer center between 1998- 2019 was performed (n = 447). Univariate multivariate identified predictors survival.Median overall survival (mOS) improved over time (6.7 months 1998-2007 to 11.8 2008-2019, p .006). Predictors worse mOS included human papillomavirus (HPV) negativity (hazard ratio [HR], 1.8; 95% confidence interval [CI], 1.2-2.6), high neutrophil/lymphocyte (HR, 2.1 [1.4-3.0], disease-free (DFI) ≤6 1.4 [1.02-2.0]), poor performance status (Eastern Cooperative Oncology Group, ≥2; HR, 1.91.1-3.4). In this cohort, 50.6% recurrences occurred within 6 treatment completion, 72.5% 1 year, 88.6% 2 years. Metachronous distant metastases were more likely occur HPV-positive disease (odds [OR], 2.3 [1.4-4.0]), DFI >6 (OR, 2.4 [1.5-4.0]), body mass index ≥30 [1.1-4.8]). Oligometastatic treated local ablative therapy associated polymetastatic 0.36; CI, 0.24-0.55).These data regarding metastasis support the clinical utility early detection recurrence. Patterns population can be used inform individualized programs as well risk-stratify eligible for trials.After (HNC), are risk prior sites or body. This study includes large group recurrent HNC examines factors outcomes patterns. Patients (HPV)-positive have good outcomes, but if they recur, may regions later than HPV-negative patients. These argue personalized follow-up schedules HNC, perhaps incorporating imaging studies novel blood tests.
Language: Английский
Citations
36
Periodontology 2000, Journal Year: 2023, Volume and Issue: 96(1), P. 250 - 280
Published: Dec. 10, 2023
The oral squamous cell carcinoma (OSCC) 5 year survival rate of 41% has marginally improved in the last few years, with less than a 1% improvement per from 2005 to 2017, higher rates when detected at early stages. Based on histopathological grading dysplasia, it is estimated that severe dysplasia malignant transformation 7%-50%. Despite these numbers, does not reliably predict its clinical behavior. Thus, more accurate markers predicting progression cancer would enable better targeting lesions for closer follow-up, especially stages disease. In this context, molecular biomarkers derived genetics, proteins, and metabolites play key roles oncology. These signatures can help likelihood OSCC development and/or have potential detect disease an stage and, support treatment decision-making responsiveness. Also, identifying reliable detection be obtained non-invasively enhance management OSCC. This review will discuss emerged different biological areas, including genomics, transcriptomics, proteomics, metabolomics, immunomics, microbiomics.
Language: Английский
Citations
29
JCI Insight, Journal Year: 2024, Volume and Issue: 9(6)
Published: Feb. 8, 2024
BACKGROUND. Transrenal cell-free tumor DNA (TR-ctDNA), which transits from the bloodstream into urine, has potential to enable noninvasive cancer detection for a wide variety of nonurologic types.
Language: Английский
Citations
9
Oral Oncology, Journal Year: 2025, Volume and Issue: 161, P. 107179 - 107179
Published: Jan. 18, 2025
Language: Английский
Citations
1
Oral Oncology, Journal Year: 2022, Volume and Issue: 126, P. 105776 - 105776
Published: Feb. 17, 2022
Language: Английский
Citations
36
Journal of Biomedical Science, Journal Year: 2023, Volume and Issue: 30(1)
Published: Aug. 9, 2023
Head and Neck cancers (HNC) are a heterogeneous group of upper aero-digestive tract cancer account for 931,922 new cases 467,125 deaths worldwide. About 90% these squamous cell origin (HNSCC). HNSCC is associated with excessive tobacco alcohol consumption infection oncogenic viruses. Genotyping tumour tissue to guide clinical decision-making becoming common practice in modern oncology, but the management patients HNSCC, cytopathology or histopathology remains mainstream diagnosis treatment planning. Due heterogeneity lack access due its anatomical location, alternative methods evaluate activities urgently needed. Liquid biopsy approaches can overcome issues such as heterogeneity, which analysis small biopsy. In addition, liquid offers repeat sampling, even tumours limitations. refers biomarkers found body fluids, traditionally blood, that be sampled provide clinically valuable information on both patient their underlying malignancy. To date, majority research has focused blood-based biomarkers, circulating DNA (ctDNA), cells (CTCs), microRNA. this review, we will focus ctDNA biomarker because robustness, presence many adaptability existing laboratory-based technology platforms, ease collection transportation. We discuss mechanisms release into circulation, technological advances ctDNA, management, some challenges translating future perspectives. provides minimally invasive method prognosis disease surveillance pave way personalized medicine, thereby significantly improving outcomes reducing healthcare costs.
Language: Английский
Citations
17
Journal of Molecular Diagnostics, Journal Year: 2023, Volume and Issue: 26(3), P. 179 - 190
Published: Dec. 15, 2023
Human papillomavirus (HPV)-associated cancers, including oropharyngeal squamous cell carcinoma (HPV + OPSCC), cervical cancer, and of the anus SCCA), release circulating tumor HPV DNA (ctHPVDNA) into blood. The diagnostic performance ctHPVDNA detection depends on approaches used individual assay metrics. A comparison these has not been systematically performed to inform expected performance, which in turn affects clinical interpretation. meta-analysis was using Ovid MEDLINE, Embase, Web Science Core Collection databases assess accuracy across cancer anatomic sites, platforms, blood components. population included patients with OPSCC, HPV-associated SCCA pretreatment samples analyzed by quantitative PCR (qPCR), digital droplet (ddPCR), or next-generation sequencing (NGS). Thirty-six studies involving 2986 met inclusion criteria. sensitivity, specificity, quality each study were assessed pooled for analysis. sensitivity greatest NGS, followed ddPCR then qPCR when pooling all studies, whereas specificity similar (sensitivity: > qPCR, P < 0.001; NGS ddPCR, = 0.014). from OPSCC more easily detected compared SCCA, overall (P 0.044). In conclusion, platform, site component must be considered interpreting results. Plasma NGS-based testing may most sensitive approach overall. papillomaviruses (HPVs) are a family oncoviruses that cause benign malignant lesions genital mucosa, upper respiratory tract, skin. More than 200 distinct types have identified, at least 14 them classified as high risk, capable tumorigenesis, specific sites.1Saraiya M. Unger E.R. Thompson T.D. Lynch C.F. Hernandez B.Y. Lyu C.W. Steinau Watson Wilkinson E.J. Hopenhayn C. Copeland G. Cozen W. Peters E.S. Huang Y. Saber M.S. Altekruse S. Goodman M.T. Typing Cancers WorkgroupU.S. assessment cancers: implications current 9-valent vaccines.J Natl Cancer Inst. 2015; 107: djv086Crossref PubMed Scopus (529) Google Scholar, 2Bzhalava D. Guan P. Franceschi Dillner J. Clifford systematic review prevalence mucosal cutaneous human types.Virology. 2013; 445: 224-231Crossref (226) 3Bouvard V. Baan R. Straif K. Grosse Secretan B. El Ghissassi F. Benbrahim-Tallaa L. Guha N. Freeman Galichet Cogliano WHO International Agency Research Monograph Working GroupA carcinogens—part B: biological agents.Lancet Oncol. 2009; 10: 321-322Abstract Full Text PDF Scholar accounts 5% cancers worldwide causes almost cases well significant proportion vaginal, vulvar, penile, anal, rectal, cancers.4de Martel Plummer Vignat Worldwide burden attributable site, country type.Int J Cancer. 2017; 141: 664-670Crossref (1283) 5Goodman Saraiya Tucker T. genotype oropharynx survival United States America.Eur 51: 2759-2767Abstract (72) 6Alemany Saunier Alvarado-Cabrero I. Quirós Salmeron Shin H.-R. Pirog E.C. Guimerà Hernandez-Suarez Felix A. Clavero O. Lloveras Kasamatsu E. Laco Tinoco Geraets D.T. Mandys Poljak Jach Verge Clavel Ndiaye Klaustermeier Cubilla Castellsagué X. Bravo I.G. Pawlita Quint W.G. Muñoz Bosch F.X. de Sanjosé VVAP Study GroupHuman type distribution anal carcinomas worldwide.Int 136: 98-107Crossref (280) 7Forman Lacey C.J. Soerjomataram Lortet-Tieulent Bruni Ferlay Bray Global related diseases.Vaccine. 2012; 30: F12-F23Crossref (1214) 8Baricevic He Chakrabarty Oliver A.W. Bailey Summers Hampson Gilbert D.C. Renehan A.G. High-sensitivity papilloma virus genotyping reveals near universal positivity carcinoma: different vaccine prevention prognosis.Eur 776-785Abstract (68) Routine screening strategies CC), pelvic examinations Papanicolaou smears, enable early contributed substantial reduction incidence early-stage cancer.9Peirson Fitzpatrick-Lewis Ciliska Warren Screening cancer: meta-analysis.Syst Rev. 2: 35Crossref (276) Scholar,10Whitlock E.P. Vesco K.K. Eder Lin J.S. Senger C.A. Burda B.U. Liquid-based cytology screen U.S. Preventive Services Task Force.Ann Intern Med. 2011; 155 (W214-5): 687-697Crossref (148) Unlike effective OPSCC) SCCA) lacking, steadily increased past few decades.11Deshmukh A.A. Suk Shiels Sonawane Nyitray Liu Gaisa M.M. Palefsky J.M. Sigel Recent trends mortality States, 2001-2015.J 2020; 112: 829-838Crossref (166) Kingdom, men surpassed rates women continues rise, despite vaccination efforts.12Lechner Jones O.S. Breeze C.E. Gilson Gender-neutral UK, rising male rates, lack awareness.Lancet Infect Dis. 2019; 19: 131-132Abstract (34) 13Centers Disease Control Prevention: Associated Papillomavirus, States—2015–2019. USCS Data Brief, no. 31. Centers Prevention, US Department Health Services, Atlanta, GA:2022https://www.cdc.gov/cancer/uscs/about/data-briefs/no31-hpv-assoc-cancers-UnitedStates-2015-2019.htm#Date accessed: December 29, 2023Google 14Tota J.E. Best A.F. Zumsteg Z.S. Gillison M.L. Rosenberg P.S. Chaturvedi A.K. Evolution epidemic States: moderation increasing younger individuals shift older individuals.J Clin 37: 1538-1546Crossref (107) 15Zhang Fakhry D'Souza Projected association US, 2020-2045.JAMA 2021; 7e212907Crossref (49) 16Chaturvedi Engels E.A. Pfeiffer R.M. Xiao Kim Jiang Sibug-Saber Wentzensen Jordan R.C. Anderson W.F. States.J 29: 4294-4301Crossref (2815) Existing diagnose monitor invasive, costly, variable accuracy, indicating need improve standard care. Circulating (ctDNA) is released secreted cells other body fluids.17Siravegna Marsoni Siena Bardelli Integrating liquid biopsies management cancer.Nat Rev 14: 531-548Crossref (1279) 18Cescon D.W. Bratman S.V. Chan S.M. Siu L.L. biopsy oncology.Nat 1: 276-290Crossref (267) 19Wan J.C.M. Massie Garcia-Corbacho Mouliere Brenton J.D. Caldas Pacey Baird Rosenfeld Liquid come age: towards implementation tumour DNA.Nat 17: 223-238Crossref (1600) 20Crowley Di Nicolantonio Loupakis biopsy: monitoring cancer-genetics blood.Nat 472-484Crossref (1348) 21Pascual Attard Bidard F.-C. Curigliano De Mattos-Arruda Diehn Italiano Lindberg Merker Montagut Normanno Pantel Pentheroudakis Popat Reis-Filho Tie Seoane Tarazona Yoshino Turner N.C. ESMO recommendations use assays report Precision Medicine Group.Ann 2022; 33: 750-768Abstract (156) 22Thierry A.R. Messaoudi Gahan P.B. Anker Stroun Origins, structures, functions oncology.Cancer Metastasis 2016; 35: 347-376Crossref (550) Results detecting ctDNA shown broad applicability, molecular profiling, adaptive treatment during therapy, minimal residual disease, recurrence detection.23Dawson S.-J. Tsui D.W.Y. Murtaza Biggs H. Rueda O.M. Chin S.-F. Dunning M.J. Gale Forshew Mahler-Araujo Rajan Humphray Becq Halsall Wallis Bentley Analysis metastatic breast cancer.N Engl 368: 1199-1209Crossref (1751) 24Chen Zhao Shi Yang Wang L.T. Kang Nie Perioperative dynamic changes lung (DYNAMIC).Clin Res. 25: 7058-7067Crossref (129) 25Bettegowda Sausen Leary R.J. Kinde Agrawal et al.Detection early- late-stage malignancies.Sci Transl 2014; 6: 224ra224Crossref (3381) 26Stejskal Goodarzi Srovnal Hajdúch van't Veer L.J. Magbanua M.J.M. nucleic acids: biology, mechanisms, relevance.Mol 2023; 22: 15Crossref (28) 27Bernard D.U. San Lucas F.A. Castillo Allenson Mulu F.C. Stephens B.M. Semaan Guerrero P.A. Kamyabi Hurd M.W. Koay Taniguchi C.M. Herman Javle Wolff Katz Varadhachary Maitra Alvarez H.A. acids associated outcomes pancreatic cancer.Gastroenterology. 156: 108-118.e104Abstract (251) 28Li R.-Y. Liang Z.-Y. real-time disease evolution response.Chin Med (Engl). 133: 2476-2485Crossref (13) 29Magbanua Swigart L.B. Wu H.-T. Hirst G.L. Yau Wolf D.M. Tin Salari Shchegrova Pawar Delson A.L. DeMichele M.C. Chien A.J. Tripathy Asare C.-H.J. Billings Aleshin Sethi Louie Zimmermann Esserman neoadjuvant-treated reflects response survival.Ann 32: 229-239Abstract (167) 30Schwarzenbach Alix-Panabières Müller Letang Vendrell J.-P. Rebillard Cell-free plasma marker prostate cancer.Clin 15: 1032-1038Crossref (211) 31Tie Tomasetti Li Springer Silliman Tacey Wong H.-L. Christie Kosmider Skinner Steel Tran Desai Haydon Hayes Price T.J. Strausberg R.L. Diaz Jr., L.A. Papadopoulos Kinzler K.W. Vogelstein Gibbs analysis detects predicts stage II colon cancer.Sci 8346ra392Crossref (963) 32Tie Cohen Simons Lee Ananda McKendrick Cho J.H. Faragher I.T. Ptak Schaeffer Dobbyn analyses markers risk benefit adjuvant therapy III cancer.JAMA 5: 1710-1717Crossref (345) 33Reinert Henriksen T.V. Christensen Sharma al.Analysis cell-free ultradeep stages I colorectal 1124-1131Crossref (470) (ctHPVDNA), advantages over somatic due smaller size viral genome its cells, making an optimal target application biopsies.34Faden D.L. diagnosis head neck cancer.Cancer Cytopathol. 130: 12-15Crossref (3) Numerous detectable serum time diagnosis. It can biomarker detect earlier care imaging.35Cao Banh Kwok Krakow Khong Bavan Bala Pinsky B.A. Colevas Pourmand Koong A.C. Kong C.S. Le Q.-T. Quantitation patients.Int Radiat Oncol Biol Phys. 82: e351-e358Abstract (97) 36Ahn J.Y.K. Zhang Z. Khan Bishop J.A. Westra Koch W.M. Califano Saliva polymerase chain reaction-based surveillance papillomavirus-related Otolaryngol Head Neck Surg. 140: 846-854Crossref 37Chera B.S. Kumar Beaty B.T. Marron Jefferys Green Goldman Amdur Sheets Dagan D.N. Weiss Grilley-Olson Zanation Hackman Blumberg Patel Weissler Tan X.M. Parker Mendenhall Gupta G.P. Rapid clearance profile 16 chemoradiotherapy correlates control 4682-4690Crossref (178) 38Chera Shen Thorp Yarbrough cancer.J 38: 1050-1058Crossref 39Hanna G.J. Lau Mahmood U. Supplee J.G. Mogili Haddad R.I. Janne Paweletz C.P. Salivary informs locoregional status advanced cancer.Oral 95: 120-126Crossref (31) 40Damerla R.R. N.Y. You Soni Shah Reyngold Katabi McBride Tsai Riaz Powell S.N. Babady N.E. Viale Higginson D.S. Detection papillomavirus-associated biopsy.JCO Precis 3PO.18.00276PubMed 41Naegele Efthymiou Das Sadow P.M. Richmon Iafrate Faden sinonasal nasopharyngeal cancers.JAMA 149: 179-181Crossref (5) 42Jeannot Becette Campitelli Calméjane M.-A. Lappartient Ruff Saada Holmes Bellet Sastre-Garau diagnosed invasive carcinoma.J Pathol 201-209Crossref (122) 43Jeannot Latouche Bonneau Beaufort Ruigrok-Ritstier Bataillon Larbi Chérif Dupain Lecerf Popovic la Rochefordière Lecuru Fourchotte Jordanova von der Leyen Tran-Perennou Legrier M.-E. Dureau Raizonville Bello Roufai Tourneau Bièche Rouzier Berns E.M.J.J. Kamal Scholl relapse 27: 5869-5877Crossref (35) 44Bernard-Tessier Jeannot Guenat Debernardi Michel Proudhon Vincent-Salomon Pierga J.-Y. Buecher Meurisse François Jary Vendrely Samalin Hajbi Baba-Hamed Borg Clinical validity ancillary epitopes-HPV02 trial.Clin 2109-2115Crossref (59) 45Naegele Hirayama Double trouble: synchronous metachronous primaries confound monitoring.Head Neck. 45: E25-E30Crossref (1) ctHPVDNA-based diagnostics improved reduced cost, shorter existing tissue-based diagnostics.46Siravegna O'Boyle Varmeh Queenan Stein Thierauf Faquin W.C. Perry S.K. Bard A.Z. Deschler D.G. Emerick K.S. Varvares M.A. Park J.C. Clark J.R. Andreu Arasa V.C. Sakai Lennerz Corcoran R.B. Wirth provides accurate rapid 28: 719-727Crossref (36) past, conventional (qPCR) common method ctDNA, but newer (and costly) techniques, droplet-digital (ddPCR) (NGS), emerged.47Postel Roosen Laurent-Puig Taly Wang-Renault Droplet-based next generation DNA: perspective.Expert Mol Diagn. 2018; 18: 7-17Crossref literature influences We tested hypothesis superior cancers. medical librarian (D.G.) following guidelines Preferred Reporting Items Systematic Reviews Meta-Analyses.48Moher Liberati Tetzlaff Altman PRISMA GroupPreferred reporting items reviews meta-analyses: statement.Ann 151 (W64): 264-269Crossref (19877) search published MEDLINE (Wolters-Kluwer, 1946–February 2022), Embase (Elsevier, 1947–February Collections (Clarivate, 1900–February 2022) designed conducted reference February 18 23, 2022. (Registration required access databases.) Search customized database. Each combination controlled vocabulary key word terms relating (head neck, cervical, penile) testing. constructed exclude non-human studies. No filters language, design, date publication, origin search, produced 251 articles (Figure 1). All references exported EndNote X7.8 Philadelphia, PA). Duplicates removed first automated process manually librarian; this left 153 articles, Covidence (Melbourne, VIC, Australia) screening, selection, data extraction. Nine subsequent found through searching thus yielding total 162 screening. Studies examined any eligible inclusion. Extracted comprised following: subsite; status; method; number assay; true-positive, false-positive, false-negative, true-negative findings; source (plasma serum); probe gene (if used); amplicon hybrid capture used). Only written English included. Titles abstracts screened independently two authors (S.N. D.A.R.-T.) full-text review. same Any disagreements settled discussion consensus between authors. duplicate comparing authors, timeframe collection, outcomes. After full text 36 remained synthesis. R 4.1.2 (R Foundation Statistical Computing, Vienna, Austria; https://cran.r-project.org) conduct statistical packages "meta" "metafor" meta-analysis. missing one values [true positive, false negative (TP, FN) true negative, positive (TN, FP)] excluded. Using random effects model, 95% confidence intervals (CIs), computed TP FN, CI TN FP. Subgroups defined differently means calculated respectively. Subsequently, separate meta-regressions test characteristic sensitivities specificities. Interstudy variability between-study variance Cochran's Q statistic. percentage variation explained heterogeneity opposed sampling error I2 two-sided 0.05 significant. Potential publication bias evaluated Quality Assessment Diagnostic Accuracy Studies-2 tool (https://www.bristol.ac.uk/population-health-sciences/projects/quadas/quadas-2). judged low answers signaling questions four domains yes no, If information sufficient, unclear used. Most flow timing index 2). Notably, standard, three patient bias. Regarding 33 test, five selection. containing (Table 135Cao Scholar,40Damerla Scholar,42Jeannot 46Siravegna Scholar,49Cabel Bernard-Tessier Héquet Féron J.-G. Brun J.-F. Benoît Rodrigues Scher
Language: Английский
Citations
17
Journal of Experimental & Clinical Cancer Research, Journal Year: 2024, Volume and Issue: 43(1)
Published: Aug. 3, 2024
Abstract Background Human papilloma virus (HPV) related cancers of the oropharynx are rapidly increasing in incidence and may soon represent majority all head neck cancers. Improved monitoring surveillance methods thus an urgent need public health. Main text The goal is to highlight current potential limitations liquid biopsy through a meta analytic study on ctHPVDNA TTMV-HPVDNA. It was performed Literature search articles published until December 2023 using three different databases: MEDLINE, Embase, Cochrane Library. Studies that evaluated post-treatment TTMV-HPVDNA patients with HPV + OPSCC, studies reporting complete data diagnostic accuracy recurrence, or which number true positives, false negatives, negatives extractable, detection viral DNA clearly defined. meta-analysis conducted following Meta-analysis Of Observational Epidemiology (MOOSE) guidelines. aim this evaluate sensitivity, specificity, TTMV by ddPCR define its efficacy clinical setting for follow up HPV-OPSCC. Conclusion 12 included provided total 1311 analysis (398 valuated 913 TTMV-HPVDNA). Pooled sensitivity specificity were 86% (95% CI: 78%-91%) 96% 91%-99%), respectively; negative positive likelihood ratios 0.072 0.057–0.093) 24.7 6.5–93.2), pooled DOR 371.66 179.1–918). area under curve (AUC) 0.81 CI, 0.67–0.91). Liquid identification cell free might identify earlier recurrence OPSCC patients. At present time, protocol needs be standardized cannot yet used setting. In future, multidimensional integrated approach links multiple clinical, radiological, laboratory will contribute obtain best follow-up strategies
Language: Английский
Citations
7
Cancers, Journal Year: 2022, Volume and Issue: 14(12), P. 2968 - 2968
Published: June 16, 2022
As the seventh most common cancer globally, head and neck cancers (HNC) exert considerable disease burden, with an estimated 277,597 deaths worldwide in 2020 alone. Traditional risk factors for HNC include tobacco, alcohol, betel nut; more recently, human papillomavirus has emerged as a distinct driver of disease. Currently, limitations screening surveillance methods often lead to identifying advanced stages, associated poor outcomes. Liquid biopsies, particular circulating tumor DNA (ctDNA), offer potential enhancing screening, early diagnosis, patients, improvements patient In this review, we examine current methodologies detecting ctDNA highlight research illustrating viral non-viral biomarker utilities treatment response, prognosis. We also summarize challenges future directions testing patients.
Language: Английский
Citations
23